Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (12240)
All Articles published online
|
Publishing Process of This Article
|
Jul 28, 2020 (publication date) through Apr 24, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Cordes F, Foell D, Ding JN, Varga G, Bettenworth D. Differential regulation of JAK/STAT-signaling in patients with ulcerative colitis and Crohn’s disease. World J Gastroenterol 2020; 26(28): 4055-4075 [PMID: 32821070 DOI: 10.3748/wjg.v26.i28.4055] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v26/i28/4055.htm |
| Number | Citing Articles |
| 1 |
Cindy C.Y. Law, Maia Kayal, Saurabh Mehandru, Jean-Frédéric Colombel. A critical review of upadacitinib for the treatment of adults with moderately to severely active ulcerative colitis. Expert Review of Gastroenterology & Hepatology 2023; 17(2): 109 doi: 10.1080/17474124.2023.2172399
|
| 2 |
Francesca Penagini, Luisa Lonoce, Luisa Abbattista, Valentina Silvera, Giulia Rendo, Lucia Cococcioni, Dario Dilillo, Valeria Calcaterra, Gian Vincenzo Zuccotti. Dual biological therapy and small molecules in pediatric inflammatory bowel disease. Pharmacological Research 2023; 196: 106935 doi: 10.1016/j.phrs.2023.106935
|
| 3 |
Guillermo Alejandro Costaguta, Chloé Girard, Véronique Groleau, Kelly Grzywacz, Martha Heather Dirks, Colette Deslandres. The Role of Tofacitinib in the Treatment of Acute Severe Colitis in Children. Journal of the Canadian Association of Gastroenterology 2024; 7(2): 196 doi: 10.1093/jcag/gwad042
|
| 4 |
Manish Purohit, Gaurav Gupta, Obaid Afzal, Abdulmalik Saleh Alfawaz Altamimi, Sami I. Alzarea, Imran Kazmi, Waleed Hassan Almalki, Monica Gulati, Indu Pal Kaur, Sachin Kumar Singh, Kamal Dua. Janus kinase/signal transducers and activator of transcription (JAK/STAT) and its role in Lung inflammatory disease. Chemico-Biological Interactions 2023; 371: 110334 doi: 10.1016/j.cbi.2023.110334
|
| 5 |
Antonio Speciale, Maria Sofia Molonia, Claudia Muscarà, Mariateresa Cristani, Federica Lina Salamone, Antonella Saija, Francesco Cimino. An overview on the cellular mechanisms of anthocyanins in maintaining intestinal integrity and function. Fitoterapia 2024; 175: 105953 doi: 10.1016/j.fitote.2024.105953
|
| 6 |
Gopalsamy Rajiv Gandhi, Thiruchenduran Mohana, Kumaraswamy Athesh, Varghese Edwin Hillary, Alan Bruno Silva Vasconcelos, Mariana Nobre Farias de Franca, Monalisa Martins Montalvão, Stanislaus Antony Ceasar, Gnanasekaran Jothi, Gurunagarajan Sridharan, Ricardo Queiroz Gurgel, Baojun Xu. Anti-inflammatory natural products modulate interleukins and their related signaling markers in inflammatory bowel disease: A systematic review. Journal of Pharmaceutical Analysis 2023; 13(12): 1408 doi: 10.1016/j.jpha.2023.09.012
|
| 7 |
Jonathan W. Wallace, David A. Constant, Timothy J. Nice. Interferon Lambda in the Pathogenesis of Inflammatory Bowel Diseases. Frontiers in Immunology 2021; 12 doi: 10.3389/fimmu.2021.767505
|
| 8 |
Keren Bahar Halpern, Yael Korem Kohanim, Adi Biram, Yotam Harnik, Adi Egozi, Oran Yakubovsky, Ziv Shulman, Shalev Itzkovitz. The cellular states and fates of shed intestinal cells. Nature Metabolism 2023; 5(11): 1858 doi: 10.1038/s42255-023-00905-9
|
| 9 |
Yaxin Zhang, Guan Jiang. Application of JAK inhibitors in paradoxical reaction through immune-related dermatoses. Frontiers in Immunology 2024; 15 doi: 10.3389/fimmu.2024.1341632
|
| 10 |
Izabel Patik, Naresh S. Redhu, Alal Eran, Bin Bao, Anubhab Nandy, Ying Tang, Shorouk El Sayed, Zeli Shen, Jonathan Glickman, James G. Fox, Scott B. Snapper, Bruce H. Horwitz. The IL-10 receptor inhibits cell extrinsic signals necessary for STAT1-dependent macrophage accumulation during colitis. Mucosal Immunology 2023; 16(3): 233 doi: 10.1016/j.mucimm.2023.02.006
|
| 11 |
Lidiya V. Boldyreva, Maryana V. Morozova, Snezhanna S. Saydakova, Elena N. Kozhevnikova. Fat of the Gut: Epithelial Phospholipids in Inflammatory Bowel Diseases. International Journal of Molecular Sciences 2021; 22(21): 11682 doi: 10.3390/ijms222111682
|
| 12 |
Menglong Zou, Wei Zhang, Ying Zhu, Yin Xu. Identification of 6 cuproptosis-related genes for active ulcerative colitis with both diagnostic and therapeutic values. Medicine 2023; 102(43): e35503 doi: 10.1097/MD.0000000000035503
|
| 13 |
Bingzhou Bao, Chao Zhu, Jian Shi, Canxing Lu. Causal association between inflammatory bowel disease and hidradenitis suppurativa: A two-sample bidirectional Mendelian randomization study. Frontiers in Immunology 2023; 14 doi: 10.3389/fimmu.2023.1071616
|
| 14 |
Shubhra Mishra, Anuraag Jena, Rinkalben Kakadiya, Vishal Sharma, Vineet Ahuja. Positioning of tofacitinib in treatment of ulcerative colitis: a global perspective. Expert Review of Gastroenterology & Hepatology 2022; 16(8): 737 doi: 10.1080/17474124.2022.2106216
|
| 15 |
Kenneth Ernest-Suarez, Remo Panaccione. Update on the role of upadacitinib in the treatment of adults with moderately to severely active ulcerative colitis. Therapeutic Advances in Gastroenterology 2023; 16: 175628482311582 doi: 10.1177/17562848231158235
|
| 16 |
Weidong Xie, Haojie Jiang, Yao Chen, Huanhao Zhang, Yaoyu Song, Zhaojie Yu, Huayan Gu, Hongkai Xu, Saiyi Han, Sen Li, Naxin Liu, Shaoliang Han. Association between systemic lupus erythematosus and inflammatory bowel disease in European and East Asian populations: a two-sample Mendelian randomization study. Frontiers in Immunology 2023; 14 doi: 10.3389/fimmu.2023.1199896
|
| 17 |
Olga Hartwig, Maryam A. Shetab Boushehri, Karim S. Shalaby, Brigitta Loretz, Alf Lamprecht, Claus-Michael Lehr. Drug delivery to the inflamed intestinal mucosa – targeting technologies and human cell culture models for better therapies of IBD. Advanced Drug Delivery Reviews 2021; 175: 113828 doi: 10.1016/j.addr.2021.113828
|
| 18 |
Suresh Yeola, Ilaria Badagnani, Xiaojun Huang, Nathanial L. Segraves, Miroslav Rapta, Marie T. Borin, Glenmar P. Obedencio, William L. Fitch, Thomas A. Baillie, David L. Bourdet. The metabolic fate of izencitinib, a gut-selective pan-JAK inhibitor, in humans. Identification of unusual fecal metabolites and implications for MIST evaluation. Medicinal Chemistry Research 2023; 32(9): 2071 doi: 10.1007/s00044-023-03143-6
|
| 19 |
Jing Liu, Chengguo Zong, Xin Yu, Yan Ding, Bing Chang, Ruoyu Wang, Lixuan Sang. Alanyl-Glutamine (Ala-Gln) Ameliorates Dextran Sulfate Sodium (DSS)-Induced Acute Colitis by Regulating the Gut Microbiota, PI3K-Akt/NF-κB/STAT3 Signaling, and Associated Pulmonary Injury. ACS Infectious Diseases 2023; 9(4): 979 doi: 10.1021/acsinfecdis.3c00014
|
| 20 |
Kentaro Kojima, Kenji Watanabe, Mikio Kawai, Soichi Yagi, Koji Kaku, Maiko Ikenouchi, Toshiyuki Sato, Koji Kamikozuru, Yoko Yokoyama, Tetsuya Takagawa, Masahito Shimizu, Shinichiro Shinzaki. Real-world efficacy and safety of tofacitinib treatment in Asian patients with ulcerative colitis. World Journal of Gastroenterology 2024; 30(13): 1871-1886 doi: 10.3748/wjg.v30.i13.1871
|
| 21 |
Iris Stolzer, Anja Dressel, Mircea T. Chiriac, Markus F. Neurath, Claudia Günther. An IFN-STAT Axis Augments Tissue Damage and Inflammation in a Mouse Model of Crohn's Disease. Frontiers in Medicine 2021; 8 doi: 10.3389/fmed.2021.644244
|
| 22 |
Linshan Duan, Shuyu Cheng, Long Li, Yanling Liu, Dan Wang, Guoyan Liu. Natural Anti-Inflammatory Compounds as Drug Candidates for Inflammatory Bowel Disease. Frontiers in Pharmacology 2021; 12 doi: 10.3389/fphar.2021.684486
|
| 23 |
Han‐Qi Wang, Qi‐Wen Man, Fang‐Yi Huo, Xin Gao, Hao Lin, Su‐Ran Li, Jing Wang, Fu‐Chuan Su, Lulu Cai,, Yi Shi, Bing Liu,, Lin‐Lin Bu. STAT3 pathway in cancers: Past, present, and future. MedComm 2022; 3(2) doi: 10.1002/mco2.124
|
| 24 |
Neeraj Narula, Hasan Hamam. Selective JAK1 inhibition using upadacitinib for the management of inflammatory bowel diseases. Canadian IBD Today 2023; doi: 10.58931/cibdt.2023.1S1121
|
| 25 |
Iris Stolzer, Barbara Ruder, Markus F. Neurath, Claudia Günther. Interferons at the crossroad of cell death pathways during gastrointestinal inflammation and infection. International Journal of Medical Microbiology 2021; 311(3): 151491 doi: 10.1016/j.ijmm.2021.151491
|
| 26 |
Jing Chen, Bixin Shen, Zhengli Jiang. Traditional Chinese medicine prescription Shenling BaiZhu powder to treat ulcerative colitis: Clinical evidence and potential mechanisms. Frontiers in Pharmacology 2022; 13 doi: 10.3389/fphar.2022.978558
|
| 27 |
Alessandro Mannucci, Ferdinando D’Amico, Ahmad El Saadi, Laurent Peyrin-Biroulet, Silvio Danese. Filgotinib for moderately to severely active ulcerative colitis. Expert Review of Gastroenterology & Hepatology 2022; 16(10): 927 doi: 10.1080/17474124.2022.2138857
|
| 28 |
Axel Dignass, Philip Esters, Cathrin Flauaus. Upadacitinib in Crohn’s disease. Expert Opinion on Pharmacotherapy 2024; : 1 doi: 10.1080/14656566.2024.2333964
|
| 29 |
Shadi Aghamohammad, Amin Sepehr, Seyedeh Tina Miri, Saeideh Najafi, Mohammad R. Pourshafie, Mahdi Rohani. Investigation of the anti-inflammatory effects of native potential probiotics as supplementary therapeutic agents in an in-vitro model of inflammation. BMC Complementary Medicine and Therapies 2023; 23(1) doi: 10.1186/s12906-023-04153-y
|
| 30 |
Yafei Guo, Yang Li, Qiang Cao, Leilei Ye, Junmei Wang, Mei Guo. The Function of Natural Polysaccharides in the Treatment of Ulcerative Colitis. Frontiers in Pharmacology 2022; 13 doi: 10.3389/fphar.2022.927855
|
| 31 |
Bo Chen, Xinqian Dong, Jin Long Zhang, Xitong Sun, Lin Zhou, Kangning Zhao, Hualiang Deng, Zhen Sun. Natural compounds target programmed cell death (PCD) signaling mechanism to treat ulcerative colitis: a review. Frontiers in Pharmacology 2024; 15 doi: 10.3389/fphar.2024.1333657
|
| 32 |
Shubrata Khedkar, Minhaj Ahmad Khan. An in vitro study elucidating the synergistic effects of aqueous cinnamon extract and an anti-TNF-α biotherapeutic: implications for a complementary and alternative therapy for non-responders. BMC Complementary Medicine and Therapies 2024; 24(1) doi: 10.1186/s12906-024-04438-w
|
| 33 |
Haonan Ruan, Jiashuo Wu, Fangqing Zhang, Ziyue Jin, Jiao Tian, Jing Xia, Jiaoyang Luo, Meihua Yang. Zearalenone Exposure Disrupts STAT-ISG15 in Rat Colon: A Potential Linkage between Zearalenone and Inflammatory Bowel Disease. Toxins 2023; 15(6): 392 doi: 10.3390/toxins15060392
|
| 34 |
Manxiu Huai, Mingliang Pei, Jiaxing Pan, Yun Zhu, Yingwen Chen, Peng Du, Yanming Duan, Huixiong Xu, Wensong Ge. Oral colon-targeted responsive alginate/hyaluronic acid-based hydrogel propels the application of infliximab in colitis. International Journal of Biological Macromolecules 2023; 249: 125952 doi: 10.1016/j.ijbiomac.2023.125952
|
| 35 |
Yingyu Lu, Yonger Chen, Yuhua Li, Shuoxi Xu, Dawei Lian, Jian Liang, Dongxu Jiang, Shuxian Chen, Shaozhen Hou. Monotropein inhibits colitis associated cancer through VDR/JAK1/STAT1 regulation of macrophage polarization. International Immunopharmacology 2023; 124: 110838 doi: 10.1016/j.intimp.2023.110838
|
| 36 |
Sudheendra Hebbar Subramanyam, Judit Turyne Hriczko, Angeliki Pappas, Angela Schippers, Nobert Wagner, Kim Ohl, Klaus Tenbrock. Tofacitinib fails to prevent T cell transfer colitis in mice but ameliorates disease activity. Scientific Reports 2023; 13(1) doi: 10.1038/s41598-023-30616-w
|
| 37 |
Isabelle Lethen, Kristina Lechner-Grimm, Michael Gabel, Annkathrin Knauss, Raja Atreya, Markus F Neurath, Benno Weigmann. Tofacitinib Affects M1-like and M2-like Polarization and Tissue Factor Expression in Macrophages of Healthy Donors and IBD Patients. Inflammatory Bowel Diseases 2023; doi: 10.1093/ibd/izad290
|
| 38 |
Tao Yang, Xiao Ma, Ruilin Wang, Honghong Liu, Shizhang Wei, Manyi Jing, Haotian Li, Yanling Zhao. Berberine inhibits IFN-γ signaling pathway in DSS-induced ulcerative colitis. Saudi Pharmaceutical Journal 2022; 30(6): 764 doi: 10.1016/j.jsps.2022.03.015
|
| 39 |
Dalia O. Saleh, Nesma M.E. Abo El-Nasr, Ahmed M. Fayez, Kawkab A. Ahmed, Reem A. Mohamed. Uro-protective role of chrysin against cyclophosphamide-induced hemorrhagic cystitis in rats involving the turning-off NF-κB/P38-MAPK, NO/PARP-1 and STAT-3 signaling cascades. Chemico-Biological Interactions 2023; 382: 110585 doi: 10.1016/j.cbi.2023.110585
|
| 40 |
Meitong Guo, Xiaoyan Wang. Pathological mechanism and targeted drugs of ulcerative colitis: A review. Medicine 2023; 102(37): e35020 doi: 10.1097/MD.0000000000035020
|
| 41 |
Wei-Ming Zhong, Xiao-Hang Qian, Zhe-Wu Jin. Identification of potential predictive biomarkers and biological pathways and the correction with immune infiltration in the activation of Crohn’s disease. Immunogenetics 2022; 74(6): 527 doi: 10.1007/s00251-022-01274-5
|
| 42 |
Rui-Bin Zhang, Long-Cong Dong, Yuan Shen, Hong-Ying Li, Qin Huang, Shu-Guang Yu, Qiao-Feng Wu. Electroacupuncture alleviates ulcerative colitis by targeting CXCL1: evidence from the transcriptome and validation. Frontiers in Immunology 2023; 14 doi: 10.3389/fimmu.2023.1187574
|
| 43 |
Nathalie Bravenboer, Angela E. Oostlander, Adriaan A. van Bodegraven. Bone loss in patients with inflammatory bowel disease: cause, detection and treatment. Current Opinion in Gastroenterology 2021; 37(2): 128 doi: 10.1097/MOG.0000000000000710
|
| 44 |
Vishwas Mishra, Avipsa Bose, Shashi Kiran, Sanghita Banerjee, Idrees A. Shah, Pooja Chaukimath, Mudasir M. Reshi, Swarna Srinivas, Anaxee Barman, Sandhya S. Visweswariah. Gut-associated cGMP mediates colitis and dysbiosis in a mouse model of an activating mutation in GUCY2C
. Journal of Experimental Medicine 2021; 218(11) doi: 10.1084/jem.20210479
|
| 45 |
Taku Kobayashi, Masato Hoshi, Akira Yuasa, Shoko Arai, Mitsunobu Ikeda, Hiroyuki Matsuda, Seok-Won Kim, Toshifumi Hibi. Cost-Effectiveness Analysis of Tofacitinib Compared with Biologics in Biologic-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan. PharmacoEconomics 2023; 41(5): 589 doi: 10.1007/s40273-023-01254-x
|